Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant lactoferrin - Ventria Bioscience

Next Previous
Search
Drug Profile

Recombinant lactoferrin - Ventria Bioscience

Alternative Names: rhLactoferrin; VEN 100; VEN 101; VEN 120; VEN 130; VEN 140; VEN 150

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ventria Bioscience
  • Developer Johns Hopkins University; Minneapolis Medical Research Foundation; Rocky Mountain Poison and Drug Center; University of Colorado at Denver; Ventria Bioscience
  • Class Anti-inflammatories; Antibacterials; Antidiarrhoeals; Antineoplastics; Glycoproteins; Iron binding proteins; Recombinant proteins
  • Mechanism of Action Immunomodulators; Macrophage stimulants; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammation
  • No development reported Inflammatory bowel diseases
  • Discontinued Diarrhoea; Liver failure; Osteoporosis

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases in USA (PO)
  • 24 Mar 2023 VEN 120 is still in phase I trials for inflammatory diseases in USA (Ventria pipeline, March 2023)
  • 25 Feb 2019 Ventria Bioscience completes a phase II trial in Inflammation (In the elderly) in USA (PO) (NCT02968992)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top